Key Points • BsAbs are safe and effective in frail and older patients with MM.• Advanced age, worse PS, and higher comorbidity burden do not predict inferior outcomes with BsAbs… Click to show full abstract
Key Points • BsAbs are safe and effective in frail and older patients with MM.• Advanced age, worse PS, and higher comorbidity burden do not predict inferior outcomes with BsAbs in myeloma.
Keywords:
receiving bcma;
bcma directed;
directed bispecific;
outcomes frail;
patients receiving;
frail patients
Journal Title: Blood Advances
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!